Diaceutics Reports 39% Revenue Growth and Record EBITDA in FY 2024

Diaceutics Delivers Knockout Performance: 39% Revenue Surge & EBITDA Milestone

If you’ve been tracking the precision medicine space, today’s Diaceutics RNS isn’t just impressive – it’s a full-throated declaration that this Belfast-born player is punching well above its weight. Let’s unpack why these numbers matter more than your average corporate update.

The Numbers That Make You Sit Up Straight

Diaceutics isn’t just growing – it’s accelerating like a Tesla in Ludicrous Mode:

• £32.2m revenue (+39% constant currency) – smashing through the £30m barrier
• £4.2m adjusted EBITDA (+50%) – proving scale benefits are kicking in
• £16.8m ARR (+23%) – the recurring revenue flywheel spins faster
• £12.7m cash (+£1m in Q1 2025) – war chest intact despite growth investments

But here’s the kicker: Their April 2025 YTD sales are up 93% in TCV terms. That’s not momentum – that’s escape velocity.

Where’s This Rocket Fuel Coming From?

1. The PMx Game-Changer

Their Precision Medicine Commercialization (PMx) solution isn’t just selling – it’s evolving mid-flight. The initial £4.3m contract signed in August 2024 ballooned to £13m by March 2025 through extensions. This isn’t upselling – it’s customers voting with their wallets.

2. Enterprise Lock-In

• 7 enterprise clients (from 4 in 2023)
• £10.6m ARR from these whales
• 92% revenue from US-based pharma (up from 88%)

Translation: They’re becoming embedded in Big Pharma’s operational DNA.

3. Data That Talks (And Sells)

DXRX Signal identified 600,000+ patients for therapies in 2024. That’s not “data” – that’s commercial ammunition for clients. No wonder 18 of the top 20 pharma companies are now on board.

Leadership Chess Moves

CEO Ryan Keeling’s strategy reads like a playbook for scaling deep tech:

• Opened US HQ in New Jersey – going straight for the lion’s share of pharma spend
• 7 new VP hires – including a Chief People Officer to maintain culture at scale
• Shift to agentic AI – automating insights while keeping human oversight

The kicker? They’ve transitioned from 3% recurring revenue in 2021 to 53% today. That’s not a pivot – that’s a full business model transformation.

The Elephant in the Room: Profitability

Yes, they’re still loss-making (£1.9m PBT loss). But crucially:

• Operating loss narrowed 22% YoY
• Gross margin jumped 5pp to 88% (software-like margins in healthcare? Yes please)
• R&D spend hit £3.6m (+80%) – expensed not capitalised (transparency play)

CFO Nick Roberts’ message is clear: “The investment phase is in the rearview.” With H2 weighting increasing (62% of 2024 revenue came in H2), 2025’s profitability target looks achievable.

Risks? Let’s Be Adults

• US macro uncertainty – but 71% jump in FDA precision medicine approvals suggests tailwinds
• Order book dipped 6% to £24.9m – but next 12 months’ visibility up 44%
• Customer concentration – 14.5% from top client (down from 15.4%)

Smart hedge: They’re expanding into “diagnostically powered therapies” beyond traditional precision medicine – a market they estimate could hit 1,000 therapies by 2030.

The Bottom Line for Investors

Diaceutics is executing the rare triple play:

1. Outsized growth in a structural growth market
2. Transition to high-margin recurring revenue
3. US commercial ramp just hitting stride

With £13.7m cash (April 2025) and trading at 3.6x EV/Sales (based on £32.2m revenue), this remains a compelling growth story. The question isn’t “if” they’ll hit profitability – it’s “how high” the margin ramp goes post-2025.

As the precision medicine wave crests, Diaceutics isn’t just riding it – they’re steering the ship. Will this be the UK’s next breakout healthcare tech story? The numbers suggest we’re watching Act II of something special.